Ország: Egyesült Királyság
Nyelv: angol
Forrás: MHRA (Medicines & Healthcare Products Regulatory Agency)
Leflunomide
DE Pharmaceuticals
L04AA13
Leflunomide
20mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 10010300
_créé le_ _par_ _modifié le_ _par_ _Laboratoires_ _Pays_ 16/04/2014 E WASCZCZYK 21/05/2014 E WASCZCZYK SANOFI UK _Couleur_ _Nbre/Réf._ 1 PROCESS BLACK U _Version N°_ 3 _Type Article_ NOTICE TRIPLE LEFLUNOMIDE R772190 20 MG CPRS _Nom du produit_ _Référence article_ _Dosage_ _Quantité_ _N° version Logo/Name_ _N° version Country Ex._ _N° plan Dimensionnel_ _N° plan positionnement_ _Dimensions_ _Taille mini_ _caractères_ NA NA 1-606251A 606251-1A 150 X 210 MM 9 PTS _Numéro de Pages_ 1 / 6 _Code sécurité_ R772190 COMPIÈGNE COMPIÈGNE PACKAGE LEAFLET: INFORMATION FOR THE USER LEFLUNOMIDE WINTHROP ® 20 MG FILM-COATED TABLETS leflunomide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Leflunomide Winthrop is and what it is used for 2. What you need to know before you take Leflunomide Winthrop 3. How to take Leflunomide Winthrop 4. Possible side effects 5. How to store Leflunomide Winthrop 6. Contents of the pack and other information 1. WHAT LEFLUNOMIDE WINTHROP IS AND WHAT IT IS USED FOR Leflunomide Winthrop belongs to a group of medicines called anti-rheumatic medicines. It contains the active substance leflunomide. Leflunomide Winthrop is used to treat adult patients with active rheumatoid arthritis or with active psoriatic arthritis. Symptoms of rheumatoid arthritis include inflammation of joints, swelling, difficulty moving and pain. Other symptoms that affect the entire body include loss of appetite, fever, loss of energy and anaemia (lack of red blood cells). Symp Olvassa el a teljes dokumentumot
OBJECT 1 LEFLUNOMIDE 20MG TABLETS Summary of Product Characteristics Updated 19-Feb-2015 | Zentiva • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Leflunomide Winthrop 20 mg film-coated tablets 2. Qualitative and quantitative composition Each tablet contains 20 mg of leflunomide. Excipients with known effect: Each tablet contains 72 mg of lactose monohydrate. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet. Yellowish to ochre and triangular film-coated tablet, imprinted with ZBO on one side. 4. Clinical particulars 4.1 Therapeutic indications Leflunomide is indicated for the treatment of adult patients with: • active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), • active psoriatic arthritis. Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has Olvassa el a teljes dokumentumot